Vimarsana
Biggest News Aggregation in the World

Page 21 - Longitudinal Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Longitudinal Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Longitudinal Study Today - Breaking & Trending Today

Childcare is about early education and learning for kids, not just getting more women into the workforce - Vimarsana News

Childcare is about early education and learning for kids, not just getting more women into the workforce

Childcare needs qualified staff who can trigger the start of the education process, not mere childminders to enable the lifting of workforce numbers.

Source: afr.com
Crosswords and chess may help more than socialising in avoiding dementia - Vimarsana News

Crosswords and chess may help more than socialising in avoiding dementia

People who kept their mind active with literacy and mental acuity tasks were up to 11 percent less likely to develop dementia than their peers, according to a new study.

Source: rnz.co.nz
What Is Rejection Sensitive Dysphoria? Causes & Treatment - Vimarsana News

What Is Rejection Sensitive Dysphoria? Causes & Treatment

Here, we will explain the mental health condition of Rejection Sensitive Dysphoria (RSD), and give the best treatment in 2023.

'Life is too short; it does not matter what age you are - you need to grab life' – The Irish Times - Vimarsana News

'Life is too short; it does not matter what age you are - you need to grab life' – The Irish Times

Promoting elder wellbeing: Active Retirement Ireland is crystal clear that social interaction and its cognitive and physical benefits are key components to a longer, healthier life

Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association - Vimarsana News

Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association

The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the safety and efficacy of AT-001 (caficrestat) in improving or preventing worsening of cardiac functional capacity in Diabetic Cardiomyopathy (DbCM); topline data from the study is expected...